CA3224043A1 - Use of mazdutide - Google Patents
Use of mazdutide Download PDFInfo
- Publication number
- CA3224043A1 CA3224043A1 CA3224043A CA3224043A CA3224043A1 CA 3224043 A1 CA3224043 A1 CA 3224043A1 CA 3224043 A CA3224043 A CA 3224043A CA 3224043 A CA3224043 A CA 3224043A CA 3224043 A1 CA3224043 A1 CA 3224043A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- uric acid
- administered
- medicament
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110711050.0 | 2021-06-25 | ||
| CN202110711050 | 2021-06-25 | ||
| PCT/CN2022/100878 WO2022268174A1 (zh) | 2021-06-25 | 2022-06-23 | Mazdutide的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3224043A1 true CA3224043A1 (en) | 2022-12-29 |
Family
ID=84544128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3224043A Pending CA3224043A1 (en) | 2021-06-25 | 2022-06-23 | Use of mazdutide |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240293513A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4360641A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024524273A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240027053A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117597135A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022298841A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3224043A1 (cg-RX-API-DMAC10.html) |
| TW (2) | TW202617173A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022268174A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023281591A1 (en) * | 2022-06-01 | 2025-01-02 | Innovent Biologics (Suzhou) Co., Ltd. | Treatment method using mazdutide |
| EP4788362A1 (en) * | 2023-10-03 | 2026-08-12 | Innovent Biologics (Suzhou) Co., Ltd. | Methods of treating diabetes and obesity |
| EP4788356A1 (en) * | 2023-10-03 | 2026-08-12 | Innovent Biologics (Suzhou) Co., Ltd. | Methods of treating adolescent obesity |
| WO2025098422A1 (zh) * | 2023-11-07 | 2025-05-15 | 深圳信立泰药业股份有限公司 | 多重受体共激动剂化合物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| AU2023281591A1 (en) * | 2022-06-01 | 2025-01-02 | Innovent Biologics (Suzhou) Co., Ltd. | Treatment method using mazdutide |
-
2022
- 2022-06-23 TW TW114124620A patent/TW202617173A/zh unknown
- 2022-06-23 CA CA3224043A patent/CA3224043A1/en active Pending
- 2022-06-23 US US18/573,602 patent/US20240293513A1/en active Pending
- 2022-06-23 TW TW111123396A patent/TW202300171A/zh unknown
- 2022-06-23 KR KR1020247003005A patent/KR20240027053A/ko active Pending
- 2022-06-23 WO PCT/CN2022/100878 patent/WO2022268174A1/zh not_active Ceased
- 2022-06-23 AU AU2022298841A patent/AU2022298841A1/en active Pending
- 2022-06-23 CN CN202280045316.5A patent/CN117597135A/zh active Pending
- 2022-06-23 JP JP2023579334A patent/JP2024524273A/ja active Pending
- 2022-06-23 EP EP22827666.3A patent/EP4360641A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240293513A1 (en) | 2024-09-05 |
| JP2024524273A (ja) | 2024-07-05 |
| TW202300171A (zh) | 2023-01-01 |
| EP4360641A4 (en) | 2025-10-22 |
| CN117597135A (zh) | 2024-02-23 |
| EP4360641A1 (en) | 2024-05-01 |
| TW202617173A (zh) | 2026-05-01 |
| AU2022298841A1 (en) | 2024-01-25 |
| WO2022268174A1 (zh) | 2022-12-29 |
| KR20240027053A (ko) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240293513A1 (en) | Use of mazdutide | |
| CN1462191B (zh) | Glp-1用于制备治疗急性冠脉综合征的药物的用途 | |
| EP2324853B1 (en) | Lixisenatide as add-on to metformin in the treatment of diabetes type 2 | |
| US20110118180A1 (en) | Method of treatment of diabetes type 2 comprising add-on therapy to metformin | |
| KR102231074B1 (ko) | 인슐린 글라진/릭시세나티드 고정비 제형 | |
| US20250296973A1 (en) | Treatment method using mazdutide | |
| AU2019229469B2 (en) | GLP-1 composition for treating obesity and weight management | |
| McFarlane | Antidiabetic medications and weight gain: implications for the practicing physician | |
| HK40110048A (en) | Use of mazdutide | |
| KR20110052990A (ko) | 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법 | |
| HK40118093A (en) | Treatment method using mazdutide | |
| WO2025073289A1 (en) | Methods of treating diabetes and obesity | |
| RU2834226C2 (ru) | Композиция glp-1 для лечения ожирения и регулирования веса | |
| EP4531894A1 (en) | Methods of using a gcg/glp1 co-agonist for therapy | |
| Das et al. | New Horizons in T2DM Management: A Review of Emerging Antidiabetic Medications | |
| CA2685636C (en) | Method of treatment of diabetes type 2 comprising add-on therapy to metformin | |
| WO2026046202A1 (zh) | Glp-1/gip肽或含有其的药物组合物的用途 | |
| TW202140061A (zh) | 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑 | |
| İMAMOĞLU | BASIC ASPECTS OF ANTIDIABETIC DRUGS AND TREATMENT IN TYPE 2 DIABETES MELLITUS | |
| AU2009238272A1 (en) | Method of treatment of diabetes type 2 comprising add-on therapy to metformin | |
| HK40013213A (en) | Glp-1 composition for treating obesity and weight management | |
| Sorbera et al. | Insulin glulisine | |
| HK40056898A (en) | Glp-1 composition for treating obesity and weight management | |
| JP2021528424A (ja) | 対象における食後のグルコースレベルをコントロールする方法および使用 | |
| KR20110052987A (ko) | 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241028 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250319 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| R19 | Request for party data change rejected |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R19-R122 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED NOT COMPLIANT Effective date: 20250513 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250513 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250513 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250514 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250605 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250605 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250605 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260512 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260512 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260622 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260622 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260622 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260723 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260723 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260723 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260723 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260723 |